Alnylam Pharmaceuticals (ALNY) Receivables - Net (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Receivables - Net came in at $912.7 million in Q2 2026, up 60.95% YoY from $567.1 million in Q2 2025, and up 3.26% on a QoQ basis from $884.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Receivables - Net (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Receivables - Net data on file, last reported at $912.7 million in Q2 2026.
- Quarterly Receivables - Net rose 60.95% year-over-year to $912.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $912.7 million (up 60.95% YoY) and the FY2025 annual result came in at $777.6 million, up 91.85% from the prior year.
- Receivables - Net climbed to $912.7 million in Q2 2026, from $884.0 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $964.8 million in Q3 2025 to a low of $142.3 million in Q2 2022.
- A 5-year average of $429.4 million and a median of $326.6 million in 2023 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net slipped 2.94% — and 2025, when it soared 172.65%.
- Tracing ALNY's Receivables - Net over 5 years: stood at $238.0 million in 2022, then surged by 37.75% to $327.8 million in 2023, then grew by 23.65% to $405.3 million in 2024, then soared by 91.85% to $777.6 million in 2025, then rose by 17.38% to $912.7 million in 2026.
- The last three Receivables - Net figures came in at $912.7 million (Q2 2026), $884.0 million (Q1 2026), and $777.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 912.74 Mn |
| Jun 30, 2026 | 912.74 Mn |
| Mar 31, 2026 | 883.96 Mn |
| Mar 31, 2026 | 883.96 Mn |
| Dec 31, 2025 | 777.57 Mn |
| Dec 31, 2025 | 777.57 Mn |
| Sep 30, 2025 | 964.77 Mn |
| Sep 30, 2025 | 964.77 Mn |
| Jun 30, 2025 | 567.11 Mn |
| Jun 30, 2025 | 567.11 Mn |
| Mar 31, 2025 | 418.04 Mn |
| Mar 31, 2025 | 418.04 Mn |
| Dec 31, 2024 | 405.31 Mn |
| Dec 31, 2024 | 405.31 Mn |
| Sep 30, 2024 | 353.85 Mn |
| Sep 30, 2024 | 353.85 Mn |
| Jun 30, 2024 | 309.48 Mn |
| Jun 30, 2024 | 309.48 Mn |
| Mar 31, 2024 | 321.38 Mn |
| Mar 31, 2024 | 321.38 Mn |